


## PHARMACEUTICAL 2021

## Greenwich LifeSciences Inc. Rank 28 of 409





## PHARMACEUTICAL 2021



## Greenwich LifeSciences Inc. Rank 28 of 409

The relative strengths and weaknesses of Greenwich LifeSciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Greenwich LifeSciences Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 175% points. The greatest weakness of Greenwich LifeSciences Inc. is the variable Revenues, reducing the Economic Capital Ratio by 30% points.

The company's Economic Capital Ratio, given in the ranking table, is 154%, being 508% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	28,660
Cost of Goods Sold	0
Intangible Assets	16
Liabilities, Current	1,045
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	0.83
Property and Equipment	0
Research and Development	1,058
Revenues	0
Selling, General and Administrative Expense	806

Output Variable	Value in 1000 USD
Assets	28,677
Liabilities	1,045
Expenses	1,864
Stockholders Equity	27,631
Net Income	-1,863
Comprehensive Net Income	-1,863
Economic Capital Ratio	154%